+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vasculitis Treatment Market by Treatment Type, Disease Type, Administration Route, End User, Distribution Channel - Global Forecast to 2030- Product Image
Vasculitis Treatment Market by Treatment Type, Disease Type, Administration Route, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Vasculitis Treatment Market by Treatment Type, Disease Type, Administration Route, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888985
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vasculitis Treatment Market grew from USD 202.92 million in 2024 to USD 213.64 million in 2025. It is expected to continue growing at a CAGR of 5.23%, reaching USD 275.68 million by 2030.

Unveiling the Evolving Landscape of Vasculitis Treatment

Vasculitis encompasses a diverse group of conditions characterized by inflammation of blood vessels, leading to a wide spectrum of clinical manifestations and therapeutic challenges. From small vessel diseases to large vessel pathologies, each subtype presents unique considerations in diagnosis, treatment, and patient management. Recent advancements in immunology and targeted therapies have begun to reshape treatment paradigms, yet unmet needs remain in optimizing patient outcomes and cost efficiency.

Against this backdrop, our executive summary synthesizes the most pressing trends, competitive dynamics, and regulatory factors influencing the vasculitis treatment landscape. Drawing on comprehensive primary interviews and rigorous secondary research, this analysis provides a panoramic view of current market forces and emerging opportunities. By highlighting transformative shifts, segmentation insights, and regional dynamics, we offer a strategic framework to inform investment decisions and portfolio prioritization.

This introduction sets the stage for an in-depth exploration of market drivers, headwinds, and actionable recommendations. Whether evaluating pipeline investments, refining go-to-market strategies, or assessing regional expansion, stakeholders will find the distilled insights essential for charting a course through an increasingly complex therapeutic arena.

Emerging Paradigm Shifts Reshaping Therapeutic Approaches

The vasculitis treatment landscape is undergoing a profound transformation driven by breakthroughs in biologics, precision medicine, and digital health integration. For decades, corticosteroids and broad-spectrum immunosuppressants formed the backbone of therapy, but rising concerns about long-term toxicity and variable efficacy have spurred investment in targeted agents.

Today, monoclonal antibodies and small molecules designed to modulate specific inflammatory pathways are gaining traction, offering improved safety profiles and sustained remission rates. Advances in genomic profiling and biomarker discovery are enabling clinicians to stratify patients more accurately and tailor regimens to individual disease phenotypes. Simultaneously, telemedicine platforms and remote monitoring tools are enhancing patient adherence and real-world evidence collection, accelerating adaptive regulatory pathways.

Regulatory bodies have responded to these innovations with expedited review processes and adaptive licensing frameworks, fostering a more agile ecosystem for drug development. As a result, strategic partnerships between biotech firms, contract research organizations, and academic centers are proliferating, driving a more collaborative and efficient pipeline. These converging forces are redefining therapeutic possibilities and opening new avenues for both established and emerging players.

Assessing the Ripple Effects of 2025 US Tariffs on Treatment Supply Chains

The introduction of new import tariffs announced in 2025 has reverberated across the vasculitis treatment supply chain, influencing pricing structures, sourcing strategies, and market access dynamics. Many biologic therapies, which rely on complex raw materials and specialized manufacturing processes, have seen increased landed costs. These pressures have been particularly acute in the United States, where payers and providers are negotiating more aggressively to contain rising expenditures.

In response, manufacturers are optimizing logistics by diversifying supplier networks and exploring onshore production options to mitigate tariff exposure. Several leading developers have initiated capacity expansions in domestic facilities, aiming to secure supply continuity and reduce dependency on international sites. Pricing strategies have also evolved, with payers leveraging value-based contracting and outcome-linked rebates to balance budgetary constraints with patient access.

Over the long term, the tariff environment is prompting a recalibration of investment priorities. Companies are accelerating efforts to develop next-generation formulations and administration routes that enhance convenience and reduce overall health system burdens. By adapting to this new cost paradigm, innovators can preserve margins while maintaining competitive differentiation in a dynamic regulatory and reimbursement landscape.

Deep Dive into Market Segmentation Drivers and Trends

An in-depth segmentation analysis reveals nuanced drivers across multiple dimensions of the vasculitis treatment market. When examining therapies by type, biologics represent a rapidly expanding category, buoyed by the clinical success of rituximab and tumor necrosis factor inhibitors such as adalimumab, etanercept, and infliximab. Corticosteroids remain entrenched as first-line interventions, while immunosuppressants including azathioprine, cyclophosphamide, methotrexate, and mycophenolate mofetil continue to address refractory cases. Plasma exchange serves as a critical adjunct for severe or rapidly progressive forms of the disease.

Disease-based segmentation underscores distinct epidemiological and therapeutic patterns. ANCA-associated vasculitis leads in incidence and therapeutic innovation, whereas rare conditions like Behçet’s disease and Takayasu arteritis present specialized treatment challenges. Giant cell arteritis and IgA vasculitis also demand differentiated approaches, with emerging agents targeting vascular remodeling and immune complex deposition.

Administration route plays a pivotal role in patient adherence and clinical outcomes. Intravenous infusions offer precise dosing control but require hospital settings, prompting a shift toward subcutaneous injections and oral formulations that enhance convenience. End user analysis highlights a diverse provider network spanning ambulatory care centers, outpatient clinics, acute care hospitals, and specialty centers, each with unique procurement and reimbursement frameworks. Finally, distribution through hospital pharmacies, online channels, and traditional retail outlets shapes accessibility and cost dynamics, influencing patient choice and payer negotiations.

Regional Dynamics Shaping Vasculitis Treatment Adoption

Regional market behavior in the Americas is governed by a combination of robust healthcare infrastructure, high per-capita spending, and advanced reimbursement mechanisms. In the United States and Canada, payer mandates encourage integration of value-based contracting and real-world evidence to validate therapeutic benefits. Meanwhile, Latin American markets exhibit variable access due to pricing disparities, prompting tiered market entry strategies focused on public health programs and regional alliances.

Across Europe, the Middle East, and Africa, regulatory harmonization under frameworks such as the European Medicines Agency streamlines cross-border approvals, while emerging economies in the Gulf Cooperation Council and North Africa offer growth potential despite reimbursement fragmentation. Governments in these regions are increasingly prioritizing rare disease registries and specialized treatment centers to enhance patient management and data collection.

In the Asia-Pacific arena, diverse market maturity levels range from highly sophisticated systems in Japan and Australia to cost-conscious environments in Southeast Asia. Accelerating domestic R&D investments, coupled with government incentives for biosimilar adoption, are reshaping competitive dynamics. Strategic partnerships between global pharmaceutical companies and local manufacturers facilitate technology transfer and drive more affordable treatment options.

Competitive Landscape and Strategic Positioning of Leading Players

The competitive landscape is dominated by established pharmaceutical and biotech leaders alongside nimble innovators advancing novel modalities. Roche remains a pivotal player through its leadership in rituximab, while AbbVie has solidified its position with adalimumab, leveraging extensive real-world datasets to support expanded indications. Johnson & Johnson’s infliximab franchise continues to evolve through next-generation biosimilar licensing agreements, enhancing affordability and market reach.

Several mid-sized companies are making strategic inroads with pipeline assets targeting key inflammatory pathways. Emerging firms are investing in novel small molecules and bispecific antibodies designed to improve efficacy and minimize off-target effects. Partnerships between large cap firms and these emerging players facilitate accelerated clinical development and shared commercial infrastructure.

Collaborative ventures extend into diagnostics and digital health, with companies co-developing companion diagnostics to identify patients most likely to respond to targeted therapies. This convergence of therapeutic and diagnostic innovation underscores a trend toward precision medicine, enabling differentiated positioning in a crowded market. As biosimilars continue to gain traction, incumbent innovators are focusing on lifecycle management strategies, including improved formulations and extended dosing intervals, to sustain market share.

Strategic Imperatives to Capitalize on Market Opportunities

Industry leaders should prioritize investment in personalized treatment algorithms by integrating biomarker discovery and digital patient monitoring. Tailoring interventions to specific vasculitis subtypes will enhance clinical outcomes and increase payer willingness to reimburse premium therapies. Collaborative research partnerships with academic centers and specialty clinics can accelerate identification of predictive biomarkers.

Optimizing supply chains to mitigate cost pressures from global trade policies is imperative. Manufacturers and distributors must explore localized production capabilities and agile logistics networks to maintain reliable access, safeguard margins, and navigate evolving tariff frameworks. Value-based contracting models should be extended to align stakeholder incentives and share performance risks.

Stakeholders also need to embrace patient engagement tools, from remote monitoring apps to telehealth platforms, to boost adherence and capture real-world evidence. This data can underpin adaptive regulatory submissions and support outcomes-based reimbursement. By fostering cross-functional collaboration across R&D, commercial, and market access teams, organizations can drive holistic strategies that secure competitive advantage in a dynamic market.

Robust Methodological Framework Ensuring Data Accuracy

Our research methodology combines rigorous secondary data analysis with comprehensive primary research to ensure robust and actionable insights. Secondary sources include peer-reviewed journals, regulatory filings, clinical trial registries, and proprietary industry databases. These inputs provide foundational context on epidemiology, clinical guidelines, reimbursement policies, and competitive activity.

Primary research comprises in-depth interviews with key opinion leaders, specialty clinicians, payers, and industry executives. These qualitative dialogues offer perspectives on emerging clinical practices, market access challenges, and investment priorities. Interview findings are systematically triangulated against quantitative data to validate trends and forecast implications.

Data analysis employs both descriptive and inferential statistical techniques, enabling segmentation analysis, scenario modeling, and sensitivity testing. Continuous validation through expert advisory panels ensures methodological rigor and mitigates bias. The resulting insights are synthesized into thematic narratives that inform strategic decision-making across therapy development, commercialization, and market expansion.

Synthesis of Insights Guiding Future Vasculitis Treatment Strategies

In conclusion, the vasculitis treatment market stands at an inflection point defined by innovative biologics, shifting regulatory paradigms, and evolving payer expectations. Our analysis underscores the importance of targeted segmentation, adaptive supply chain strategies, and precision medicine approaches to unlock sustainable growth. Regional dynamics reveal differentiated opportunities, with developed markets driving premium adoption and emerging regions offering volume potential through biosimilar and public health initiatives.

Competitive and collaborative models continue to redefine how novel therapies reach patients, while tariff pressures incentivize logistical resilience and cost optimization. By acting on the strategic imperatives outlined, stakeholders can navigate this complex landscape, advance patient care, and secure market leadership. This executive summary provides the insights necessary to inform portfolio prioritization, partnership decisions, and market access strategies in the evolving vasculitis therapeutic arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Biologics
      • Rituximab
      • Tumor Necrosis Factor Inhibitors
        • Adalimumab
        • Etanercept
        • Infliximab
    • Corticosteroids
    • Immunosuppressants
      • Azathioprine
      • Cyclophosphamide
      • Methotrexate
      • Mycophenolate Mofetil
    • Plasma Exchange
  • Disease Type
    • ANCA Associated Vasculitis
    • Behcet Disease
    • Giant Cell Arteritis
    • IgA Vasculitis
    • Takayasu Arteritis
  • Administration Route
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Ambulatory Care Centers
    • Clinics
    • Hospitals
    • Specialty Centers
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • ChemoCentryx, Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vasculitis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Biologics
8.2.1. Rituximab
8.2.2. Tumor Necrosis Factor Inhibitors
8.2.2.1. Adalimumab
8.2.2.2. Etanercept
8.2.2.3. Infliximab
8.3. Corticosteroids
8.4. Immunosuppressants
8.4.1. Azathioprine
8.4.2. Cyclophosphamide
8.4.3. Methotrexate
8.4.4. Mycophenolate Mofetil
8.5. Plasma Exchange
9. Vasculitis Treatment Market, by Disease Type
9.1. Introduction
9.2. ANCA Associated Vasculitis
9.3. Behcet Disease
9.4. Giant Cell Arteritis
9.5. IgA Vasculitis
9.6. Takayasu Arteritis
10. Vasculitis Treatment Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Vasculitis Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Clinics
11.4. Hospitals
11.5. Specialty Centers
12. Vasculitis Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Vasculitis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vasculitis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vasculitis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. ChemoCentryx, Inc.
16.3.3. AbbVie Inc.
16.3.4. Johnson & Johnson
16.3.5. Bristol-Myers Squibb Company
16.3.6. Amgen Inc.
16.3.7. UCB S.A.
16.3.8. Novartis AG
16.3.9. Pfizer Inc.
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VASCULITIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. VASCULITIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. VASCULITIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VASCULITIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 62. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. CANADA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 64. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 66. CANADA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 113. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. ITALY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 137. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. ITALY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 139. ITALY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 145. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 147. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 191. QATAR VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. QATAR VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 193. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 194. QATAR VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 195. QATAR VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 227. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 233. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 234. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 251. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. POLAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. POLAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. POLAND VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 257. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. POLAND VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 259. POLAND VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 278. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. CHINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 280. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. CHINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 282. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 283. CHINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 284. CHINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. INDIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. INDIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 288. INDIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. INDIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 290. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 291. INDIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 292. INDIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 296. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 298. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 300. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 327. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITO

Companies Mentioned

The companies profiled in this Vasculitis Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • ChemoCentryx, Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 213.64 Million
Forecasted Market Value ( USD ) by 2030 $ 275.68 Million
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vasculitis Treatment - Global Strategic Business Report - Product Image

Vasculitis Treatment - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
ANCA Vasculitis - Pipeline Insight, 2025 - Product Image

ANCA Vasculitis - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Vasculitis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Vasculitis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Giant-Cell Arteritis Market Report 2025 - Product Image

Giant-Cell Arteritis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Angiotensin Converting Enzyme Inhibitors Market by Molecule Type, Chemical Class, Dosage Form, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030 - Product Image

Angiotensin Converting Enzyme Inhibitors Market by Molecule Type, Chemical Class, Dosage Form, Route Of Administration, Indication, Distribution Channel - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From

About the Market

Vasculitis is a group of diseases that cause inflammation of the blood vessels. It can affect any organ in the body, but is most commonly seen in the heart, lungs, and kidneys. Vasculitis drugs are used to treat the inflammation and reduce the risk of organ damage. These drugs are typically immunosuppressants, which work by suppressing the immune system and reducing inflammation. Common vasculitis drugs include corticosteroids, cyclophosphamide, and methotrexate. In addition to these drugs, there are also biologic agents, such as rituximab and tocilizumab, which are used to treat more severe cases of vasculitis. These drugs are designed to target specific parts of the immune system, and are often used in combination with other treatments. The vasculitis drug market is an important part of the cardiovascular drug market, as it provides treatments for a wide range of conditions. Companies in this market include Pfizer, Merck, AbbVie, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.